E

Enliven Therapeutics
D

ELVN

21.280
USD
-0.31
(-1.44%)
مغلق
حجم التداول
14,031
الربح لكل سهم
-2
العائد الربحي
-
P/E
-11
حجم السوق
1,255,312,414
أصول ذات صلة
A
AKRO
-0.810
(-1.47%)
54.180 USD
A
AXS
0.640
(0.63%)
102.580 USD
المزيد
المقالات

العنوان: Enliven Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.